Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with suppressive properties that preferentially expand in cancer. Myeloid-derived suppressor cells mainly suppress T-cell proliferation and cytotoxicity, inhibit natural killer cell activation, and induce the differentiation and expansion of regulatory T cells. The wide spectrum of MDSC suppressive activity in cancer and its role in tumor progression have rendered these cells a promising target for effective cancer immunotherapy. In this review we briefly discuss the origin of MDSCs and their main mechanisms of suppression and focus more on the approaches developed up to date targeting of MDSCs in tumor-bearing animals and cancer patients.
''E's'' in cancer immunoediting theory that consists of 3 main phases: elimination, equilibrium, and escape. 1 It has been well established that the immune system is a key player during tumor development, playing ambivalent roles in tumor elimination and tumor progression. Immune cells can recognize tumor-associated antigens 2 and eliminate tumor cells through numerous anti-tumor mechanisms. However, during tumor development, tumor factors in the tumor microenvironment modulate immune cells toward a protumorigenic phenotype leading to local and/or systemic immunosuppression, thus inducing tumor growth and establishing a suppressive niche in distant sites facilitating tumor metastasis. This unique interaction between tumor and immune cells in the tumor microenvironment has rendered immunotherapy a daunting task in our battle against cancer.
The tumor microenvironment exclusively promotes the induction and expansion of immune suppressors that ultimately inhibit effector T-cell proliferation and the activation of cytotoxic T lymphocytes (CTLs) and anti-tumor natural killer (NK) cells. Earlier studies have described the presence of natural suppressors of lymphoproliferative responses with myeloid cell characteristics in mice and humans. 3Y7 The finding that suppressive monocytes expressing CD11b/Mac-1 accumulate in the spleens of tumor-bearing mice 8 has led to the identification of T-cell suppressors that express CD11b/Mac-1 and Gr-1 antigens in the spleens of mice immunized with highly immunogenic recombinant anticancer vaccines and tumor-bearing mice. 9Y12 A plethora of following studies in various cancer models have identified these cells as a heterogeneous population of cells with myeloid origin that has the potential to differentiate into mature granulocytes, macrophages, and dendritic cells (DCs), but under the influence of tumor factors are hampered in an immature state of differentiation with potent immunesuppressive functions. This heterogeneous population of myeloid suppressive cells is collectively known as myeloid-derived suppressor cells (MDSCs). 13 Heterogeneity and T-cell suppression are hallmarks of MDSC biology. In mice, MDSCs are classified into 2 main subsets according to its morphology and markers: CD11b + Ly6C high Ly6G j cells resemble monocytes and are called monocytic MDSCs (M-MDSCs), and CD11b + Ly6G + Ly6C low/int cells with a polymorphonuclear morphology are called granulocytic MDSCs (G-MDSCs) or polymorphonuclear MDSCs. 14, 15 The absence of a Gr-1 homolog in humans led to the inclusion of a broader spectrum of markers in the description of suppressive myeloid cells in cancer patients. In general, M-MDSCs express CD14 j CD33 + HLA j DR low CD11b + , whereas G-MDSCs express CD14 j CD33 + HLA-DR low CD11b + CD15 + and/or CD66b + (reviewed in Gabrilovich et al. 16 ). Monocytic MDSCs expressing Lin j CD11b + CD14 + have also been described in patients with melanoma. 17 It is clearly noted that the expression of a unique marker of immunosuppression in MDSCs in mice and humans has been one of the main challenges in the field.
The fact that MDSC immune suppression can be reversed in vitro and in vivo has led to the development of a multitude of strategies in cancer therapy. Herein, we briefly discuss MDSC origin and mechanisms of immune suppression, focusing more on the therapeutic strategies targeting MDSCs in tumor-bearing mice and cancer patients.
MDSC ORIGIN
During differentiation, hematopoietic stem cells diverge at a ''decision-making point'' to common lymphoid progenitors to generate NK cells, T cells, or B cells or common myeloid progenitors to generate monocytes, granulocytes, macrophages, DCs, megakaryocytes, and erythrocytes in the presence of appropriate factors. 18 Because MDSCs are a heterogeneous population of monocytic or granulocytic cells with a suppressive property, their origin and factors determining their fate, phenotype, and function in cancer are controversial and need to be further elucidated. A common monocyte progenitor from monocyte-macrophage DC progenitor that gives rise to monocytes or monocyte-derived macrophages was recently identified. 19 Under inflammatory conditions, common monocyte progenitors differentiate into monocytes, which can further differentiate into tissue-resident macrophages, 19 consistent with the finding that MDSCs in the tumor microenvironment differentiate toward tumor-associated macrophages via hypoxiainducible factor > induced by tumor hypoxic conditions. 20 Myeloid-derived suppressor cells can be induced from bone marrow (BM) precursors in the presence of the tumor-derived factors granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 6 (IL-6). 21 Inhibition of paired immunoglobulin-like receptor B or C/EBPA promotes MDSC differentiation to macrophages, granulocytes, and DCs with no suppressive function, suggesting that the suppressive function of MDSCs induced by tumor factors is reversible. 21, 22 The origin and fate of Ly6C high and Ly6C low monocytes are subject to further exploration, especially that Ly6C high monocytes with suppressive properties identified as M-MDSCs have been widely studied in inflammation and cancer. It is still controversial whether Ly6C high monocytes differentiate to Ly6C low monocytes or whether both monocyte subsets arise from independent precursors. 23Y27 In EL4 mouse thymoma-bearing mice, splenic Ly6C high (Gr1 int CD11b + ) M-MDSCs transferred to tumorbearing mice are able to give rise to all CD11b + subsets including Gr-1 high granulocytes. 28 Similarly, Youn et al. 29 recently demonstrated that M-MDSCs (CD11b + Ly6C high ) in tumor-bearing mice could differentiate into G-MDSCs expressing CD11b + Ly6G + Ly6C j . This differentiation was mediated by epigenetic silencing of the retinoblastoma gene in M-MDSCs mediated by histone deacytylase 2. These findings highlight M-MDSC plasticity and its potential to give rise to G-MDSCs. It is still debatable whether G-MDSCs consist solely of immature myeloid cells with suppressive function or whether mature neutrophils can acquire suppressive properties in the tumor milieu. A study by Fridlender et al. 30 identifies transforming growth factor (TGF-A) as the inducer of suppressive neutrophils in the tumor (N 2 ), because blockade of TGF-A enhances the recruitment and activation of neutrophils with anti-tumor functions (N 1 ), suggesting that neutrophils can be polarized in tumor-bearing animals or potentially in cancer patients toward a suppressive phenotype. Transcriptomic analysis revealed differences between tumor-associated neutrophils (TANs), splenic G-MDSCs, and neutrophils from naive mice. 31 Compared with neutrophils from naive mice, TANs display lower expression of cell-cytotoxicity genes, a higher expression of major histocompatibility complex (MHC) II genes and inflammatory cytokines (e.g., tumor necrosis factor > [TNF-], IL-1>/A), and upregulation of chemoattractants of T cells, B cells, neutrophils, and macrophages. Interestingly, neutrophils from naive animals are more closely related to splenic G-MDSCs than to TANs. Unlike neutrophils from naive mice, splenic G-MDSCs are immune suppressive and express higher levels of macrophage colony-stimulating factor receptor (M-CSFR), CD244, arginase, myeloperoxidase, and reactive oxygen species (ROS), with a lower phagocytic activity. 32 A recent study has reported that tumorpromoting neutrophils are recruited to the tumors by tumor-derived oxysterols in a CXCR2-dependent manner, promoting tumor growth and neoangiogenesis. 33 Future studies will further unveil the exact origin of MDSCs and its relation to other myeloid subsets in cancer.
MDSC MECHANISMS OF SUPPRESSION
Tumor-infiltrating immune cells with a suppressive phenotype include regulatory T cells (Tregs), FC T cells, 34, 35 suppressive tumor-associated macrophages, and MDSCs. The detailed mechanisms of MDSC suppression were recently described elsewhere. 16, 36, 37 Herein, we briefly highlight the main suppressive mechanisms used by MDSCs in cancer.
Although MDSC subsets share the ability to suppress T-cell activation, their different mechanisms of function, recruitment, and expansion in tumor-bearing animals are being constantly highlighted. In general, MDSC expansion is induced by tumor factors such as GM-CSF, 38 stem cell factor (SCF-1), 39 prostanglandin E 2 (PGE 2 ), 40 cyclooxygenase 2 (COX-2), 41 vascular endothelial growth factor (VEGF), 42 macrophage CSF, and IL-6. 43 Myeloid-derived suppressor cells suppress T-cell activity mainly by modulating L-arginine metabolism through the up-regulation of arginase 1 (Arg1) and inducible nitric oxide synthase (iNOS) in M-MDSCs and Arg1 and ROS up-regulation in G-MSDCs. 37 Arginase 1 catalyzes the conversion of L-arginine to L-ornithine, whereas iNOS mediates NO production from L-arginine, ultimately leading to the production of urea. 37 L-Arginine starvation induces the loss of the CD3X chain 44 and inhibition of T-cell cycle progression by restraining the up-regulation of cyclin D 3 and cyclin-dependent kinase 4. 45 In addition, NO induces Fasdependent apoptosis 46 and inhibits proteins downstream IL-2 receptor. 47 Moreover, reactions between NO and ROS, such as superoxide ions, produce peroxynitrite that impact CD8 + T-cell activity by inducing the nitration of CD8 + T-cell receptor restraining its recognition by the MHC peptide. 36 Myeloid-derived suppressor cells also deprive T cells from cystein, an essential amino acid required for T-cell activation. 48 T cells do not produce cysteine and depends on antigen-presenting cells (APCs) for cysteine supply after they uptake cystine. However, MDSCs limit cystine pool available for APCs depriving T cells from cysteine. 48 Monocytic MDSC and G-MDSC suppressive activities are thought to also diverge in the expression and phosphorylation of signal transducers and activators of transcription (STATs). Granulocytic MDSC suppressive functions are thought to be mainly mediated by STAT3 phosphorylation, whereas STAT1 seems to play a main role in M-MDSC suppressive biology. 36 Current studies show that STAT3 phosphorylation is a key event in regulating G-MDSC suppressive activity and inhibition of differentiation through various mechanisms. STAT3 phosphorylation enhances the production of ROS through the activation of calcium-binding proteins S100A9 and S100A8, 49 which are involved in the formation of NAPDH oxidase complex (Nox-2). 50 In addition, up-regulation of Nox-2 subunits, such as p47 phox and gp91 phox , is directly related to the enhanced production of ROS by G-MDSCs augmenting its suppressive activity. 36 STAT3 not only promotes the suppressive activity and expansion of MDSCs, but also induces tumorigenesis by mediating the production of myeloid-derived angiogenic factors such as VEGF. 51 STAT3 immunosuppressive functions of MDSCs can also be mediated by Hsp72 from tumor-derived exosomes. 52 On the other hand, M-MDSC suppressive activities are mediated by factors that regulate Arg1 and iNOS production, such as STAT1. STAT1 activation is mediated by interferon F (IFN-F) and IL-1A and is thought to play an important role in M-MDSC suppressive activity because of the fact that blocking IFN-F or disrupting STAT1 partially reduced M-MDSC suppressive functions. 14 However, a recent study demonstrated that expression of IFN-F and IL-4R> is not required for T-cell suppression by MDSCs, because MDSCs from IFN-F j/j , IFN-FR j/j , and IL-4R> j/j tumor-bearing mice suppress CD8 + and CD4 + T cells. 53 Myeloid-derived suppressor cell immunosuppression also extends to a vast network of immune cells including Tregs, macrophages, and NK cells. Myeloid-derived suppressor cells induce the recruitment and expansion of Tregs in tumor-bearing mice through the production of IL-10 and TGF-A, 54 dependent on CD40-CD40L interaction. 55 Interleukin 10 production by MDSCs also decreases IL-12 production in macrophages enhancing T H 2 responses in tumor bearers. 56 However, a controversial report demonstrated that TGF-A mediated generation of induced Tregs (CD4 + CD25 + Foxp3 + ) and proliferation of natural Tregs are impaired by G-MDSCs. 57 Natural killer cell activity is also suppressed by MDSCs. Myeloid-derived suppressor cells from the liver and spleen of tumor-bearing mice inhibit NK cell cytotoxicity, NKG2D expression and IFN-F through membranebound TGF-A in tumor bearers, 58 or NKp30 receptor expression on NK cells in patients with hepatocellular carcinoma. 59 Interestingly, a recent report has demonstrated that NK cells can be converted to MDSCs in the presence of GM-CSF. 60 However, this finding has to be further confirmed because NK cells share a common lymphoid progenitor with T and B cells but not myeloid cells. 18 
THERAPEUTIC TARGETING OF MDSCS
It is now being greatly highlighted that exploring immunosuppressive regulation by MDSCs in the tumor microenvironment will bring a new paradigm in our understanding of cancer as well as for devising novel immunotherapeutic approaches. In recent years, many approaches have been developed with the goal of abolishing their suppressive activity in vivo as a therapeutic intervention in cancer. In the following, we discuss different therapeutic strategies applied in the modulation of MDSCs in tumor-bearing mice and cancer patients including inhibition of MDSC suppressive function, expansion, recruitment, and induction of MDSC differentiation ( Fig. 1 ).
Inhibition of MDSC Suppressive Function

Inhibitor of Reactive Nitrogen Species (AT38)
Murine
Reactive nitrogen species produced by MDSCs and tumor cells such as peroxynitrite anion induces the nitration of the chemokine CCL2 preventing the migration of CTLs to the tumor core. Targeting of reactive nitrogen species with AT38 ([3-(aminocarbonyl) furoxan-4-yl] methyl salicylate) in mice bearing subcutaneous colon carcinoma expressing GM-CSF (C26GM), or thymoma expressing OVA (EG7-OVA), or spontaneous prostate cancer (TRAMP mice), down-regulated Arg1, iNOS, and peroxynitrite in MDSCs, enhanced survival, and improved the efficacy of adoptive transferred tumor-specific CTLs. 61 
Nitroaspirin
Murine
Nitric oxideYdonating aspirin (NO aspirin) consists of an aspirin molecule covalently linked to an NO donor group. The effects of different NO-donating aspirins (NCX4060, NCX4016) on MDSC suppressive activity in cancer were studied by de Santo et al. 62 In BALB/c mice inoculated with a colon adenocarcinoma expressing GM-CSF (C26-GM), treatment with NCX4060 or NCX4016 restored T-lymphocyte proliferation in MLR reactions or T cells induced with anti-CD3 and anti-CD28 in the presence of MDSCs, increased CTL activity, and reduced MDSC Arg1 and NOS activity, in vitro and in vivo. Despite these effects on MDSC suppressive function, treatment of tumor-bearing mice with NCX4016 orally did not significantly decrease tumor burden or prolonged survival except only when coupled to a recombinant DNA vaccine in 2 vaccination models:
(a) vaccination of BALB/c mice with a plasmid encoding the full-length env gene (pcDNA3-env), challenged with colon carcinoma CT26 (gp70 positive) subcutaneously, and orally treated with NXC4016 (b) immunization of BALB/c mice with a plasmid DNA encoding p186 (extracellular and transmembrane portion of HER-2/neu) before challenging with a mammary carcinoma cell line N2C.
Phosphodiesterase 5 Inhibitors (Sildenafil)
Murine Inhibition of cyclic guanosine monophosphate (cGMP) phosphodiesterase gene family 5 (PDE-5) induces apoptosis of colon cancer cells through the induction of cGMP protein kinase in colon tumor cells 63 or apoptosis of B-cell chronic lymphocytic leukemia cells in a caspase-dependent manner. 64 Treatment of mice with sildenafil, a PDE-5 inhibitor, delayed the progression of tumors in mice inoculated with different tumor cell lines including colon carcinoma (CT26WT), colon carcinoma expressing GM-CSF (C26GM), mammary adenocarcinoma (TS/A), MCA203 fibrosarcoma, 65 and a mouse transgenic melanoma model. 66 Interestingly, delayed tumor progression was associated with the modulation of T-cell immune suppression by MDSCs toward a less suppressive phenotype. Treatment of tumor-bearing mice with sildenafil given in the drinking water decreased the expression of IL-4R>, Arg1, and NOS2 in tumor-infiltrating CD11b + cells; increased the efficacy of adoptive T-cell transfer therapy (ACT); induced the infiltration of tumor-infiltrating lymphocytes (TILs) including CD8 + and CD4 + T lymphocytes 65, 66 ; partially restored the expression of CD3X chain in CD8 + and CD4 + T lymphocytes infiltrating skin melanomas and metastatic lymph nodes; and increased IL-2 levels and decreased the levels of IL-1A, VEGF, GM-CSF, IL-6, S100A9, and the chemokines CCL2 (monocyte chemoattractant protein 1) and CCL3 (macrophage inflammatory protein 1>) in metastatic lymph nodes in melanoma-bearing mice. 66 The exact mechanism of linking the accumulation of cGMP in MDSCs with L-arginine metabolism is not fully elucidated. Although sildenafil delayed tumor growth in different mice models, tumor eradication was not achieved suggesting the importance of the combined targeting of a network of immune cells with a suppressive phenotype in the tumor microenvironment.
Human
Peripheral blood mononuclear cells (PBMCs) from patients with multiple myeloma (MM) or head and neck squamous cell carcinoma (nonYsmall cell lung carcinoma [NSCLC]) stimulated in vitro with plate-coated anti-CD3/anti-CD28 Abs in the presence or absence of sildenafil or Arg1 inhibitor (NorNOHA) or NOS2 inhibitor ( L -NMMA) restored the proliferation of CD3 cells. Interestingly, sildenafil only restored the proliferation of CD8 + T cells in PBMCs from NSCLC cancer patients. CD4 + T-cell proliferation in PBMCs from MM patients was still lower than PBMCs from healthy donors. 65 More studies need to be performed to demonstrate the significance of these findings in humans, its toxicity, and its efficacy in the clearance of primary or metastatic tumors.
Triterpenoids (CDDO-Me)
Murine
Treatment of mice-bearing colon carcinoma (MC38), Lewis lung carcinoma (LLC), or EL-4 thymoma with a synthetic triterpenoid, CDDO-Me, abrogated MDSC suppressive function through the down-regulation of ROS and inhibition of STAT3 and inhibited tumor growth. In addition, CDDO-Me enhanced the efficacy of survivin vaccine in vivo. However, CDDO-Me treatment did not affect Arg1 and NO production or the frequency of MDSCs in the spleens of tumor-bearing mice. 67 
Human
Treatment of patients with locally advanced (stage II-III) or metastatic (stage IV) pancreatic cancer with CDDO-Me and Gem in a phase I clinical trial had no effects in the frequencies of MDSCs in the peripheral blood with an increased response of T cells from treated patients to tetanus toxoid and phytohemagglutinin. However, the effect of CDDO-Me treatment was not assessed in the absence of Gem. 67 
Very Small Size Proteoliposomes
Murine
Very small size proteoliposome (VSSP) is a nanoparticulated adjuvant that promotes DC maturation and enhances CD8 + T-cell effector function. Treatment of tumor-bearing mice with VSSP increases the accumulation of MDSCs in the spleen. However, MDSCs from the spleens of VSSP-treated mice are significantly less suppressive than nontreated mice, correlating with enhanced CTL activity in mice treated with VSSP. In addition, VSSP treatment induces the differentiation of MDSCs into mature APCs. 68 More studies need to be performed to evaluate VSSP efficacy in the clinic.
Inhibition of Exosome Formation (Amiloride)
Murine
Amiloride inhibits exosome formation. It has been reported that membrane-associated Hsp72 from tumor-derived exosomes induces MDSC suppressive activity by inducing the STAT3 phosphorylation in a TLR2/MyD88-dependent manner through autocrine IL-6. Treatment of mice-bearing CT26, TS/A, or EL4 tumors with exosome inhibitors such as amiloride enhanced anti-tumor immune responses when combined with cyclophosphamide. 52 However, treatment of mice with exosome inhibitors alone did not reduce tumor growth.
Human
Treatment of patients with colorectal metastatic carcinoma with amiloride for 3 weeks abrogated the suppressive activity of MDSCs from peripheral blood ex vivo and decreased the ability of autologous serum to induce STAT3 phosphorylation in MDSCs. 52 
Inhibition of MDSC Expansion
Gem and 5-Fluorouracil
Murine
Pyrimidine analogs, such as Gem and 5-fluorouracil (5-FU), have been currently used in the clinic to induce tumor cell death and hamper tumor growth. Their cytotoxic effects on MDSCs in tumor bearers have currently been described. Administration of Gem and/or 5-FU selectively induced apoptosis of Gr1 + CD11b + MDSCs in the spleens and tumors of tumor-bearing mice, with no significant decrease in the levels of CD4 + , CD8 + , B cells, NK cells, or macrophages, and enhanced IFN-F production by tumorspecific CD8 + T cells and NK cells. 69Y72 The anti-tumor effects of Gem were enhanced when combined with other therapeutic protocols including chemotherapeutic drugs, such as cyclophosphamide 73 and rosiglitazone, 74 that target Tregs and peroxisome proliferator-activated receptor F respectively, or in combination with adenoviral-based immunotherapy 75 or IFN-A treatment. 69 Despite promising effects in anti-tumor immunity, the ambivalent effects of chemotherapeutic drugs, including Gem and 5-FU, are yet to be further explored. Gemcitabine and 5-FU triggered the production of IL-1A in MDSCs following the activation of the inflammasome (NOD-like receptor family, pyrin domain containing-3 protein [Nlrp3]-dependent caspase 1 activation complex) in a cathepsin BYdependent manner. Secreted IL-1A then stimulated the production of IL-17 by CD4 + T cells inducing the expression 
COX-2 and PGE 2 Inhibitors
Murine Cyclooxygenase 2 and PGE 2 are produced by different human and murine cancer cells including LLC, renal carcinoma, colon carcinoma MCA-38, and head and neck tumors. 41 Targeting COX-2 and PGE 2 with inhibitors, such as indomethacin, 77 celecoxib, 78 meloxicam, 79 and acetylsalicylic acid, 80 augmented tumor growth in different cancer models. Cyclooxygenase 2 inhibitors reduced systemic levels of PGE 2 , modulating MDSC suppressive function, recruitment, and induction. Cyclooxygenase 2 inhibitors inhibited Arg1 expression in MDSCs induced by tumor-released factors such as COX-2 and PGE 2 , reduced ROS and NO levels, enhanced T cell anti-tumor responses, and improved the efficacy of DC-based immunotherapy in tumorbearing mice. 41, 81 Acetylsalicylic acid also regulated the recruitment of MDSCs to the tumors by decreasing the levels of MDSCattracting chemokine CCL2 and increasing the expression of CXCL10 and CTL infiltration in glioma. 80 Cyclooxygenase 2 is a PGE 2 -forming enzyme that can also be activated through PGE 2 receptor EP2 in MDSCs by PGE 2 . 40, 82 Induction of EP2 in MDSCs by PGE 2 hampered their differentiation to mature APCs from the BM 82 and induced the generation of MDSCs from monocytes in vitro by blocking monocyte differentiation to mature CD1a + DCs and enhancing the expression of indoleamine 2,3-dioxygenase, IL-4R>, NOS2, and IL-10. 83 Human CD14 + monocytes acquire MDSC phenotype through coculture with human melanoma cells through a COX-2Ydependent mechanism. 84 In patients with advanced melanoma, inhibition of PGE 2 , COX-2, STAT3, and superoxide in MDSCs restored T-cell proliferation in culture.
Sunitinib
Murine
Sunitinib, a tyrosine kinase inhibitor, targets a wide range of kinases including platelet-derived growth factor receptor, VEGF receptors (VEGFR1-VEGFR3), SCF, M-CSF, and FMSlike tyrosine kinase 3. 85Y87 Sunitinib is currently approved by the Food and Drug Administration for the treatment of patients with gastrointestinal stromal tumors that failed to respond to imatinib 85, 88 and as a first-line treatment of patients with metastatic renal cell carcinoma (RCC). 89, 90 In addition to its angiogenic effects and targeting of tumor cells, sunitinib immune modulation of suppressor cells, such as MDSCs and Tregs, has been recently described. 91Y93 Sunitinib treatment decreased the percentages of MDSCs and Tregs in the spleen of tumor bearers, reduced the expression of protumorigenic factors in TILs such as IL-10, TGF-A, Foxp3, cytotoxic T-lymphocyte antigen 4 (CTLA-4), and programmed cell death ligand 1 (PDL-1), skewing suppressed T lymphocytes toward an anti-tumor T H 1 phenotype, represented by the increased levels of IFN-F and CTL responses. 91 Sunitinib combined with IL-12 and 4-1BB activation prolonged survival of mice bearing MCA26 colon tumor and increased the anti-tumor efficacy of OVA-loaded DC vaccines in mice bearing subcutaneous B16 melanoma expressing OVA. 91, 94 However, sunitinib modulation of tumor MDSCs seems to be compromised in tumors expressing high levels of GM-CSF, such as 4T1 or human RCC cells. 95, 96 Granulocyte-macrophage CSF in the tumor microenvironment reprograms MDSCs to act independently on STAT3 through the induction of STAT5 phosphorylation, bypassing the inhibition of STAT3 phosphorylation induced by sunitinib. 92, 95, 96 Another mechanism of tumor evasion from sunitinib treatment is the increased production of the chemokine stromal cellYderived factor 1 (CXCL12) in the tumor microenvironment following p53 activation induced by sunitinib, leading to increased levels of MDSCs in RCC xenografts. 97 
Human
The clinical outcome of sunitinib treatment in patients with metastatic RCC is limited to its ability to modulate immune suppression in the tumor rather than in the periphery. 95, 96 Despite the encouraging findings that sunitinib treatment decreases the levels of MDSCs, Tregs, and IFN-F producing T lymphocytes in PBMCs of RCC patients, 98, 99 its effects on intratumoral MDSCs and proangiogenic factors such as matrix metalloproteinase 9 (MMP-9), MMP-8, and IL-8 in tumor explants were minimal. 95, 96 
Blockade of Stem Cell Factor (SCF; ckit ligand)
Murine
Stem cell factor is expressed by tumor cells, with a higher expression in large tumors. Stem cell factor production in the tumor microenvironment enhances the accumulation of MDSCs in the tumor. Stem cell factor siRNA knockdown in tumor cells and blocking SCFR-SCF binding with anti-ckit reduce MSDC expansion and infiltration in the BM and tumor, reduced angiogenesis, enhanced T-cell proliferative responses, and decreased Treg development in mice bearing MCA26 colon carcinoma. 39 Amino-Bisphosphonate (Zoledronate, Pamidronate)
Amino-bisphosphonates is an MMP-9 inhibitor. The production of MMP-9 by tumor and stromal cells is directly correlated with VEGF production in the tumor microenvironment. Targeting MMP-9 by amino-biphosphate in mice with spontaneous mammary carcinoma reduced the levels of proYMMP-9 and VEGF in the serum and tumor-enhanced BM hematopoiesis and improved anti-tumor responses induced by DNA vaccination. 100 
Doxorubicin-Cyclophosphamide Chemotherapy
Human
Myeloid-derived suppressor cells (Lin j/low CD33 + CD11b + HLA-DR j ) percentages and absolute numbers in the peripheral blood of breast cancer patients directly correlate with the stage of the disease, with patients in stage IV with extensive metastatic tumor having the highest numbers of circulating MDSCs and lowest T-cell responses. Doxorubicin and cyclophosphamide are common chemotherapeutic drugs included for the treatment of breast cancer. Interestingly, patients treated with doxorubicin-cyclophosphamide displayed increased percentages of MDSCs in the peripheral blood but not when followed with paclitaxel treatment, suggesting that treatment with doxorubicincyclophosphamide alone may not be favorable in the development of anti-tumor immune responses in patients with breast cancer. 101 
Inhibition of MDSC Recruitment
Vemurafenib
Human
Vemurafenib is a specific inhibitor of BRAF, V600E a mutation 102 that causes constitutive activation of the MAP kinase pathway, a common mutation in melanoma patients. 103 Treatment of advanced melanoma patients with vemurafenib decreased the frequencies of M-MDSCs (CD14 + HLA-DR j/low ) and G-MDSCs (CD66b + Arg1 + CD16 j/low ) in PBMCs. 102 The clinical course melanoma was correlated with an increase in the percentage or M-MDSCs and G-MDSCs, with patients responding more to treatment having lower percentages of M-MDSCs, whereas G-MDSCs percentages varied among patients. Vemurafenib treatment is thought to modulate the tumor microenvironment impacting MDSC induction because culturing PBMCs from healthy donors in a conditioned media from a primary melanoma cell line in the presence of vemurafenib failed to induce CD14 + HLA-DR j/low M-MDSCs compared with cultures with no vemurafenib. 102 However, it was not shown in this study whether vemurafenib had direct effects on MDSC suppressive functions.
AntiYGranulocyte CSF and Anti-Bv8 Antibodies
Murine
Bv8 (prokineticin 2) is up-regulated in MDSCs upon granulocyte CSF (G-CSF) receptor activation by G-CSF. 104 In tumor-bearing mice, Bv8 induced angiogenesis and MDSC mobilization from the BM to the tumor or distant sites establishing a prometastatic niche for the colonization of metastatic tumor cells. 104, 105 Overall, targeting the G-CSFYBv8 axis in tumor-bearing animals with specific antibodies decreased MDSC infiltration in the tumor and G-MDSC recruitment to the lungs of tumor-bearing mice and decreased angiogenesis, tumor growth, and metastasis.
AntiYCSF-1 Receptor (GW2580)
Murine
GW2580 is a kinase inhibitor of CSF-1 receptor (CSF1R). 106 Targeting CSF1R with GW2580 in LLC-bearing mice decreased M-MDSC infiltration in the tumor with no effect on G-MDSC recruitment and decreased the expression of Arg1 and MMP-9 in the tumors and angiogenesis. Interestingly, treatment of CSF-1 impaired tumor growth only when combined with VEGF-2 receptor. 107
Anti-CCL2 Antibody
Murine
Inflammatory monocytes expressing Gr-1 and CCR2 (CCL2 chemokine receptor), in response to CCL2 produced by tumor cells and stroma, are preferentially recruited to pulmonary metastases but not to primary tumor. Ablation of CCL2-CCR2 signaling with anti-CCL2 antibody promoted tumor survival and decreased tumor metastasis by blocking the recruitment of inflammatory monocytes to the lungs. Induction of tumor metastasis in the lungs by inflammatory monocytes was dependent on the expression of VEGFA, because inhibition of VEGFA expression in inflammatory monocytes abrogated the index of metastases in the lungs. 108
CXCR2 and CXCR4 Antagonists
Murine
Tumors with Tgfbr2 deletion induced the recruitment of MDSCs through the production of CXCL5 and stromal cellYderived factor 1, which chemoattracted MDSCs expressing CXCR2 and CXCR4. In mice inoculated with 4T1 mammary carcinoma, blockade of CXCR2 and CXCR4 significantly decreased lung metastasis with no substantial difference in the growth of the primary tumors. 109 
Induction of MDSC Differentiation
Vitamin D 3
Human
Differentiation of suppressive CD34 + myeloid progenitors to DCs by the differentiation-inducing hormone 1>, 25-hydroxyvitamin D 3 , has been reported in mice bearing LLC and patients with NSCLC. 110, 111 In a study conducted by Kulbersh et al., 111 17 NSCLC patients were either treated (11 patients) or untreated (6 patients) with 1>,25-hydroxyvitamin D 3 for 3 weeks before surgery. Analysis of CD34 + and DCs by immunohistochemistry in the NSCLC tissues revealed reduced infiltration of intratumoral CD34 + cells and immature DC-SIGN + DCs and increased numbers of intratumoral DC-LAMP + mature DCs. To assess the clinical significance of such findings, a clinical trial was conducted in 32 newly diagnosed patients with NSCLC, with 16 patients left untreated and the other 16 treated with 1>,25-hydroxyvitamin D 3 for 3 weeks before surgical removal of the tumor. 112 Immunohistochemical analysis of the tumor revealed a significant increase in the levels of intratumoral CD4 + , CD8 + T lymphocytes, and cells expressing the activation markers CD69 in patients treated with 1>,25-hydroxyvitamin D 3 . To assess the significance of these findings, NSCLC patients were monitored for tumor recurrence after surgery, with median recurrence being 181 days in the untreated group compared with 620 days in the treated group, emphasizing the importance of combining immune therapy by targeting suppressive cells to surgical or chemotherapy procedures in the treatment of cancer. In another study to determine the effects of 1>,25-hydroxyvitamin D 3 in the cytokine profiles in the plasma and tumor tissue of NSCLC patients, it was reported that 1>,25-hydroxyvitamin D 3 differently modulates the cytokine milieu in the plasma compared with tumor tissue, increasing the levels of IL-6, IL-10, IL-2, IFN-F, and TNF-> in the tumor tissue and increasing levels of IL-8, VEGF, IL-1>, and IL-1A in the plasma but not tumors of treated patients compared with the levels in untreated patients. 113 Although some studies have assessed the effects of 1>,25-hydroxyvitamin D 3 on the cytokine profile of human monocytes and macrophages in vitro, 114 more studies need to be performed to link the effects of different cytokine milieu in the tumor and plasma of cancer patients in differentiation of immunosuppressive cells to mature DCs.
In a recent report, fibrocytes expressing CD45 + CD34 + HLA-DR + with a suppressive phenotype were found to expand in patients with metastatic pediatric sarcomas, demonstrating both features of neutrophilic and monocytic cells, and suppressed antiYCD3-induced T-cell proliferation through indoleamine 2,3dioxygenase, and its expansion correlated with an increased T H 2 phenotype in patients. 115 Because 1>,25-hydroxyvitamin D 3 is believed to skew CD34 + differentiation to mature DCs, their effect in other types of cancers on suppressive CD34 + cells is still to be elucidated.
Taxanes (Docetaxel and Paclitaxel)
Docetaxel and paclitaxel are semisynthetic taxanes with anti-tumor properties. These drugs target tubulin in rapidly dividing cells, stabilizing microtubules during cell division leading to cell arrest and cell death. It has been reported in several studies that these taxanes modulate immune responses in cancer patients and tumor-bearing mice. 116, 117 Herein, we summarize the main effects of docetaxel and paclitaxel on MDSCs in murine tumor models and cancer patients.
Murine
In a murine squamous cell carcinoma model, SCC VII/SF, docetaxel in conjunction with vitamin D 3 increased the numbers of intratumoral active T cells compared with vitamin D 3 alone. However, docetaxel had no effect on the levels of CD34 + cells in the spleens and lymph nodes, and no difference in tumor weight was found between untreated mice or mice treated with vitamin D 3 and/or docetaxel. It is important to note that the efficacy of vitamin D 3 treatment in clinical trials on the recurrence of NSCLC in patients was assessed after surgery, 113 suggesting that additional procedures are required along with immune therapy in the treatment of cancer.
In a mammary carcinoma model, 4T1-Neu, intraperitoneal treatment of tumor-bearing mice significantly decreased tumor growth through the modulation of MDSCs. 118 Docetaxel treatment decreased the percentage of splenic MDSCs; decreased its suppressive activity; increased T cell CTL activity; up-regulated the expression of CCR7 (M1 marker), MHC II, CD11c, and CD86 in MDSCs; and preferentially induced cell death of mannose receptor (MR + ; M2 marker) MDSCs. Incubation of MDSCs for 6 hours decreased STAT3 phosphorylation, suggesting that docetaxel directly modulates MDSC signaling. Consistent with these findings, treatment of B16-melanomaYbearing mice with docetaxel following total body irradiation improved T-cell transfer and DC therapy, improving CTL function in vaccinated mice, by targeting highly suppressive MDSCs and blocking their rapid reconstitution following total body irradiation. 119 However, the mechanisms of docetaxel effects on MDSC differentiation and the presence of possible receptors have not been identified.
Combination of ultralow doses of paclitaxel with a peptide vaccine derived from the melanoma antigen tyrosine-related protein 2 enhanced vaccine efficiency in healthy mice. The vaccine efficiency was associated with an increase in the levels of tyrosine-related protein 2Yspecific T cells in the spleen and correlated with decreased levels of Tregs and immature myeloid cells and increased levels of effector CD8 + and CD4 + T lymphocytes in the BM and spleen and IFN-FYproducing NK cells in the BM and NK T cells in the lymph nodes. 120 Stimulation of MDSCs in vitro with paclitaxel in ultralow doses induced the expression of CD11c, CD86, and CD40 in a TLR4-independent manner, 121 suggesting that the decrease in the levels of MDSCs in paclitaxel-treated mice was due to its differentiation to DCs; however, the levels of DCs in tumor-bearing mice treated with paclitaxel were not speculated.
Human
The levels of circulating MDSCs were assessed in a clinical trial involving 41 women diagnosed with HER-2 neuYnegative breast cancer in stages II-IIIa and received 3 chemotherapeutic drugs: doxorubicin-cyclophosphamide followed by docetaxel every 3 weeks followed by NOV-002, a disodium glutathione (GSH) disulfide. 122 It was found that patients who achieved pathologic complete response (pCR) (defined as no metastatic tumor in the axillary lymph nodes, no invasive tumor in the breast, and/or invasive tumor e10mm in dimension) had lower levels of circulating MDSCs (Lin j HLA-DR j CD11b + CD33 + ) in the blood compared with patients who did not achieve pCR. In this study, 15 of 39 patients achieved a pCR, suggesting that MDSC targeting may increase the efficacy of chemotherapy regimens currently used in the clinic.
All-trans-Retinoic Acid
Murine
Retinoic acid was previously shown to induce granulocytic differentiation of cells from patients with acute promyelocytic leukemia in vitro. 123 In mice bearing subcutaneous C3 fibrosarcoma or DA3-HA mammary adenocarcinoma, treatment with subcutaneously implanted all-trans-retinoic acid (ATRA) pellets induced the differentiation of adoptively transferred MDSCs to DCs (CD11c + IA b+ ), macrophages (F4/80 + ), and granulocytes (Gr1 + CD11b j ) and improved CD4 + T-cell responses. 124 Although treatment of tumor-bearing mice with ATRA decreased the percentages of MDSCs (Gr1 + CD11b + ) in the spleens and BM of tumor-bearing mice, it did not decrease tumor growth except only when combined with a DC cell vaccine transduced with Ad-p53. 124 All-trans-retinoic acidY induced differentiation of MDSCs from tumor-bearing mice and patients with renal carcinoma was shown to be through the activation of GSH synthase and accumulation of GSH leading to a neutralization of ROS in an ERK1/2-dependent mechanism. 125 In addition, ATRA enhanced the immunogenicity and differentiation of MDSCs loaded with NK T cell ligand >-GalCer in a mechanism dependent on GSH activation in MDSCs and IFN-F production by NK T cells. 126 
Human
All-trans-retinoic acid induction of MDSC differentiation in murine models was extended to clinical trials in patients with metastatic RCC and small cell lung cancer (SCLC). 127, 128 In RCC, patients treated with ATRA before IL-2 treatment had reduced numbers of MDSCs, a higher myeloid/lymphoid DC ratio, and decreased suppressive activity of mononuclear cells. 127 Interestingly, IL-2 treatment abrogated ATRA effect. In vitro culture of MDSCs from patients with metastatic RCC with ATRA induced its differentiation to functional APCs and abrogated its immune suppression. 129 Similarly, in patients with SCLC, ATRA treatment increased DC vaccine efficacy decreasing MDSC levels in the peripheral blood and improving antigen-specific CD8 + T-cell responses. 128
TLR9 Activation by CpG
Murine
Activation of TLR9 receptor in MDSCs by CpG induced MDSC maturation and differentiation and abrogated MDSC suppressive function, especially G-MDSCs, in mice-bearing subcutaneous C26 tumors and in CEA424-Tag mice autochthonous gastric tumors. Myeloid-derived suppressor cell differentiation and inhibition of suppressive function were promoted by IFN-> produced by plasmacytoid DCs in vitro. However, the effect of IFN-> on MDSC differentiation and function needs to be further elucidated. 130 
Curcumin
Murine
In a human gastric cancer xenograft model and a mouse colon cancer allograft model, treatment with curcumin in the diet or intraperitoneally decreased the percentage of MDSCs in the tumor, spleen, and blood. Granulocytic MDSC percentage was decreased upon curcumin treatment, whereas M-MDSCs differentiated to an M1-like phenotype with an increased expression in CXCR7. Curcumin treatment of MDSCs cocultured with cancer cells or myofibroblast-conditioned medium in the presence of IL-1A inhibited p-Stat3 and IL-6 production by MDSCs. However, it was not determined in this study whether curcumin impacted MDSC suppressive function. 131 
Whole-Glucan Particles
Murine Treatment of M-MDSCs from LLC-bearing mice in vitro with whole-glucan particle (WGP) induced a population of cells expressing CD11c + F4/80 + Ly6C low . Monocytic MDSC suppressive function was also decreased upon incubation with WGP. Oral treatment of LLC-bearing mice with WGP significantly reduced the percentage of Gr-1 + CD11b + cells and Tregs and increased the percentage of macrophages, DCs, and effector CD8 + T cells in vivo, with a significant decrease in tumor burden. 132 The effects of WGP on M-MDSCs were dependent on Syk and nuclear factor JB p65 signaling.
The main therapeutic approaches applied to date in the clinic to target MDSCs in cancer patients are summarized in Table 1 .
CONCLUSION REMARKS AND FUTURE PERSPECTIVES
Chemotherapeutic protocols already established in the clinic mainly include drugs that target tumor cell proliferation and induce tumor cell death. The success of current chemotherapeutic protocols in the clinic has been limited because of the ability of cancer cells to develop resistance and evade immunosurveillance. Myeloid-derived suppressor cells have been widely described in the literature, and it is currently accepted that targeting MDSCs in the clinic is vital for the development of effective anti-tumor immunity.
One of the main challenges in MDSC research is its heterogeneity and the absence of a universal marker for immunosuppression. The availability of a wide spectrum of markers to describe different MDSC subsets in mice and the absence of a Gr-1 homolog in humans have limited the success of MDSC targeting in the clinic. The absence of unique markers has led to the lack of consensus in the literature, especially in human subject studies. In addition, because of limitations in the acquisition of tumor tissue from cancer patients, most studies describing MDSC phenotype, suppressive activity, and response to therapeutic treatment in human cancer patients are restricted to the peripheral blood. Current data from tumorbearing mice and clinical trials have revealed MDSC plasticity, with discrepancies in the responses to therapy between tumorinfiltrating MDSCs and peripheral MDSCs (e.g., spleens of tumor-bearing mice, peripheral blood of cancer patients). The presence of tumor-infiltrating MDSCs in the tumor microenvironment has rendered it more resistant to therapy in the clinic.
Thus, clinical trials designed to study the effect of therapeutic drugs on MDSC function and phenotype should consider analyzing the peripheral blood and tumor tissue. In addition, follow-up of patients involved in clinical trials should be clearly reported in studies targeting MDSCs to augment the significance of MDSC targeting in cancer and determine whether modulation of MDSCs provides the overall survival benefit for cancer patients.
